Current Report Filing (8-k)
03 Février 2023 - 02:48PM
Edgar (US Regulatory)
0001174940 false 0001174940 2023-02-01
2023-02-01 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934.
Date
of Report:
February 1, 2023
(Date
of earliest event reported)
Oragenics, Inc.
(Exact
name of registrant as specified in its charter)
|
FL |
|
001-32188 |
|
59-3410522 |
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File
Number)
|
|
(IRS
Employer
Identification
Number)
|
|
4902 Eisenhower Boulevard,
Suite 125
Tampa,
FL
|
|
33634 |
|
(Address
of principal executive offices) |
|
(Zip
Code) |
813-286-7900
(Registrant’s
telephone number, including area code)
(Former
Name or Former Address, if changed since last
report)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425) |
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12) |
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b)) |
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
|
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
|
Common Stock |
|
OGEN |
|
NYSE American |
Indicate
by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (§230.405 of
this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934
(§240.12b-2 of this chapter).
Emerging
growth company
☐
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. ☐
Item
8.01. OTHER EVENTS.
On
February 3, 2023, Oragenics, Inc. (the “Company”) announced that
the NYSE American, LLC (the “NYSE American”) had notified the
Company on February 1, 2023 that it had regained compliance with
the NYSE American continued listing standards. Specifically, the
Company has resolved the continued listing deficiency with respect
to its low selling price as described in Section 1003(f)(v) of the
NYSE American Company Guide.
Going
forward, the Company will be subject to NYSE American’s normal
continued listing monitoring. In addition, in the event that the
Company is again determined to be noncompliant with any of the
Exchange’s continued listing standards within twelve (12) months of
the notice, NYSE American will examine the relationship between the
Company’s previous noncompliance and such new event of
noncompliance and take appropriate action, which, depending on the
circumstances, may include implementing truncated compliance
procedures or immediately initiating delisting
proceedings.
A
copy of the press release announcing these events is attached as
Exhibit 99.1 to this Current Report on Form 8-K and is hereby
incorporated by reference herein.
Item
9.01 FINANCIAL STATEMENTS AND EXHIBITS.
SIGNATURES
In
accordance with the requirements of the Exchange Act, the
registrant caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized on this 3rd day
of February, 2023.
|
|
ORAGENICS,
INC.
(Registrant)
|
|
|
|
|
|
BY: |
/s/
Kimberly Murphy |
|
|
|
Kimberly
Murphy |
|
|
|
President
and Chief Executive Officer |
Oragenics (AMEX:OGEN)
Graphique Historique de l'Action
De Fév 2023 à Mar 2023
Oragenics (AMEX:OGEN)
Graphique Historique de l'Action
De Mar 2022 à Mar 2023
